Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323009 | 0.85 | MMP2 (0.48) | TAS2R14PGRKEAP1NFE2L2KDM4E | |
| SCHEMBL4316551 | 0.85 | TAS2R14 (0.45) | TAS2R14PGRKEAP1NFE2L2KDM4E | |
| SCHEMBL4313198 | 0.84 | TAS2R14 (0.44) | TAS2R14PGRKEAP1NFE2L2KDM4E | |
| SCHEMBL4310204 | 0.82 | TAS2R14 (0.45) | TAS2R14PGRKEAP1NFE2L2KDM4E | |
| SCHEMBL4318692 | 0.79 | CYP11B1 (0.48) | TAS2R14PGRKEAP1NFE2L2CYP11B1 | |
| SCHEMBL4318699 | 0.79 | CYP11B1 (0.48) | TAS2R14PGRKEAP1NFE2L2CYP11B1 | |
| SCHEMBL11948501 | 0.75 | TAS2R14 (0.54) | TAS2R14PGRKEAP1NFE2L2LMNA | |
| SCHEMBL4319421 | 0.73 | ADAMTS4 (0.48) | TAS2R14PGRKEAP1NFE2L2LMNA | |
| SCHEMBL6076540 | 0.73 | KEAP1 (0.41) | TAS2R14KEAP1NFE2L2 | |
| SCHEMBL11948510 | 0.72 | ADAMTS4 (0.59) | TAS2R14KDM4ELMNAALDH1A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001838-B1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2597083-A2 | Selective hydroxamate based MMP inhibitors | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8314148-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | MMP13, MMP11, MMP14 | TAS2R14 2291/4885PGR 2458/4885KEAP1 1648/4885 |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | MMP13, MMP11, MMP14 | TAS2R14 2291/4885PGR 2458/4885KEAP1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.